

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BESTWAY INTERNATIONAL HOLDINGS LIMITED

百威國際控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock code: 718)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Bestway International Holdings Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) hereby announces that Dr. Liu Hua (“**Dr. Liu**”) has been appointed as an executive Director with effect from 8 January 2016.

Biographical details of Dr. Liu are set out as follows:

Dr. Liu, aged 37, has over nine years of experience in the areas of equity investment and securities advisory services in the People’s Republic of China (the “**PRC**”). From January 2007 to November 2008, Dr. Liu was the investment manager of Shanghai Zhangjiang Hi-tech Park Development Co., Ltd. (上海張江高科技園區開發股份有限公司) (stock code: SH: 600895), a company listed on the Shanghai Stock Exchange, where he was responsible for equity investment of the company. From December 2008 to August 2014, he was an executive director and a member of the investment decision committee of Guotai Junan Innovation Investment Co., Ltd. (國泰君安創新投資有限公司), a wholly-owned subsidiary of Guotai Junan Securities Co., Ltd. (國泰君安證券股份有限公司) (stock code: SH: 601211), a company listed on the Shanghai Stock Exchange, where he was responsible for equity investment, establishment and management of equity investment funds and management of various investment projects of the company related to healthcare, consumer, information technology and clean technology industries. From September 2014 to November 2015, Dr. Liu was the general manager of the international business division of Donghai Securities Co., Ltd. (東海證券股份投資有限公司), the shares of which are quoted on 全國中小企業股份轉讓系統 (the National Equities Exchange and Quotations System*), where he was responsible for providing cross-border investment advisory services.

* For identification purposes only

Dr. Liu obtained a bachelor's degree in precision instrument and mechanical engineering from Tsinghua University, the PRC in July 2001, a master's degree in biomedical engineering from Imperial College London, the United Kingdom in November 2003 and a doctor's degree in bioinformatics from the University of Cambridge, the United Kingdom in December 2006.

Dr. Liu entered into an appointment letter with the Company on 8 January 2016 for an initial term of one year commencing from 8 January 2016. He is subject to retirement at the first general meeting of the Company after his appointment and thereafter subject to retirement by rotation at least once every three years and in accordance with the bye-laws of the Company. Dr. Liu is entitled to a director's remuneration of HK\$130,000 per month, which is determined with reference to the prevailing market rate and his duties and responsibilities in the Company. The remuneration of Dr. Liu is subject to review by the Board and the remuneration committee of the Company from time to time.

Dr. Liu does not have any relationships with any Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) or controlling shareholders (as defined in the Listing Rules) of the Company. Save as disclosed above, Dr. Liu did not have any directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas nor has held any other position with the Group. As at the date of this announcement, Dr. Liu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

There is no other information relating to the appointment of Dr. Liu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor any matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Dr. Liu in joining the Company.

By order of the Board
Bestway International Holdings Limited
Hu Yebi
Chairman

Hong Kong, 8 January 2016

As at the date of this announcement, the Board comprises Mr. Hu Yebi, Mr. Liu Xueheng and Dr. Liu Hua as executive Directors and Mr. Mao Kangfu, Dr. Gao Bin and Ms. Liu Yan as independent non-executive Directors.